Precision BioSciences Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Precision BioSciences, Inc. on May 27, 2021, covering events that occurred on May 26, 2021. The Company is a Delaware corporation with its principal executive offices in Durham, North Carolina, and its common stock trades on the Nasdaq Global Select Market under the symbol "DTIL". The filing primarily addresses corporate governance changes regarding executive appointments.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on personnel changes rather than financial performance data.
Material Changes
The Board of Directors made the following permanent appointments effective May 26, 2021:
- Alex Kelly: Appointed as Chief Financial Officer (CFO), transitioning from his role as Interim CFO. His employment agreement was amended to increase his annual base salary to $420,000 and his target annual bonus opportunity to 40% of his base salary, effective retroactively to January 1, 2021.
- Shane Barton: Appointed as Principal Accounting Officer, retaining his title of Vice President and Corporate Controller, transitioning from his interim role.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on business strategy, or discussion of risks and contingencies. The document is strictly limited to the disclosure of officer appointments and the terms of the amended employment agreement for the CFO.
Investor Verification Checklist
- Verify the terms of the Amended and Restated Employment Agreement for Alex Kelly (Exhibit 10.1) to confirm compensation details and tenure.
- Review the Press Release dated May 27, 2021 (Exhibit 99.1) for additional context on the leadership transition.
- Confirm the Company's status as an Emerging Growth Company and its election regarding extended transition periods for accounting standards.